Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "1mg"

25 News Found

Tata 1mg boosts delivery speed with AI-driven logistics
Supply Chain | November 12, 2025

Tata 1mg boosts delivery speed with AI-driven logistics

This partnership has led to a 10% boost in delivery speed


Lupin launches Glucagon for Injection USP, 1mg/Vial in US
News | August 11, 2025

Lupin launches Glucagon for Injection USP, 1mg/Vial in US

Glucagon is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes mellitus


Shilpa Medicare gets Europe approval for Varenicline Tablets, 0.5mg and 1mg
News | February 27, 2024

Shilpa Medicare gets Europe approval for Varenicline Tablets, 0.5mg and 1mg

Varenicline is indicated for smoking cessation in adults


Tata 1mg and Vitonnix UK get into an exclusive partnership in India
News | January 10, 2024

Tata 1mg and Vitonnix UK get into an exclusive partnership in India

Launch innovative vitamin sublingual sprays


Tata 1mg-backed 5C Network launches diagnostics-on-demand platform Prodigi PASS
Healthcare | May 24, 2023

Tata 1mg-backed 5C Network launches diagnostics-on-demand platform Prodigi PASS

5C Network’s groundbreaking platform aims to bring together diagnostic facilities and healthcare aggregators on a single platform to deliver an unparalleled patient experience


Themis gets DCGI approval of Remifentanil Hydrochloride 1mg/2mg injection for import and marketing
Drug Approval | February 18, 2023

Themis gets DCGI approval of Remifentanil Hydrochloride 1mg/2mg injection for import and marketing

Themis will market this drug with the brand name REMITHEM.


Biocon Pharma gets FDA nod for arthritis drug Tofacitinib ER
Drug Approval | November 23, 2025

Biocon Pharma gets FDA nod for arthritis drug Tofacitinib ER

Tofacitinib extended-release tablets are a Janus kinase inhibitor indicated for Rheumatoid Arthritis


NATCO launches Everolimus tablets, 1 mg
News | October 31, 2025

NATCO launches Everolimus tablets, 1 mg

Everolimus is an mTOR inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in adult patients in kidney and liver transplantation


AstraZeneca’s Baxdrostat proves effective in in Phase III trial for hard-to-control hypertension
Clinical Trials | September 05, 2025

AstraZeneca’s Baxdrostat proves effective in in Phase III trial for hard-to-control hypertension

The medicine was well tolerated, with no unexpected safety issue